Proteasome Inhibitor-Based Primary Therapy for Antibody-Mediated Renal Allograft Rejection-Reference-Cited by-同舟云学术

Proteasome Inhibitor-Based Primary Therapy for Antibody-Mediated Renal Allograft Rejection

Published:2010-02-15 Issue:3 Volume:89 Page:277-284
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:

Author:

Walsh R Carlin,Everly Jason J.,Brailey Paul,Rike Adele H.,Arend Lois J.,Mogilishetty Gautham,Govil Amit,Roy-Chaudhury Prabir,Alloway Rita R.,Woodle E Steve

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference19 articles.

1. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss.;Everly;Am J Transplant,2009

2. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.;Everly;Transplantation,2008

3. The effect of desensitization protocols on human splenic B-cell populations in vivo.;Ramos;Am J Transplant,2007

4. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production.;Perry;Am J Transplant,2009

5. Cellular mechanisms of immunologic tolerance.;Nossal;Annu Rev Immunol,1983

Cited by 162 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bortezomib for antibody‐mediated rejection of kidney transplant in youth: Associations with donor‐specific antibody;Pediatric Transplantation;2024-05-29

2. Kidney Transplantation in Multiple Myeloma and Monoclonal Gammopathy of Renal Significance;Seminars in Nephrology;2024-01

3. Current Therapies in Kidney Transplant Rejection;Journal of Clinical Medicine;2023-07-27

4. Transplantation;Clinical Immunology;2023

5. Non-Infectious Post-Transplant Complications: Disease Recurrence and Rejection;Pediatric Kidney Disease;2023